Literature DB >> 15331740

Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif.

Lai-Yee Wong1, Gerald A Matchett, Angus C Wilson.   

Abstract

In immunocompromised patients, infection with Kaposi's sarcoma-associated herpesvirus (KSHV) can give rise to Kaposi's sarcoma and several lymphoproliferative disorders. In these tumors, KSHV establishes a latent infection in many of the rapidly proliferating and morphologically abnormal cells. Only a few viral gene products are expressed by the latent virus, and one of the best characterized is the latency-associated nuclear antigen (LANA), a nuclear protein required for the maintenance of viral episomal DNA in the dividing host cell. LANA can also activate or repress an assortment of cellular and viral promoters and may contribute to pathogenesis by allowing the proliferation and survival of host cells. Here we show that activation of the human E2F1 and cyclin-dependent kinase-2 (CDK2) promoters requires elements from both the N- and C-terminal regions of LANA. Deletion of the first 22 amino acids, which are necessary for episome tethering, does not affect nuclear localization but significantly reduces transactivation. Within the deleted peptide, we have identified a short sequence, termed the chromatin-binding motif (CBM), that binds tightly to interphase and mitotic chromatin. A second chromatin-binding activity resides in the C terminus but is not sufficient for optimal transactivation. Alanine substitutions within the CBM reveal a close correlation between the transactivation and chromatin binding activities, implying a mechanistic link. In contrast to promoter activation, we find that the 223 amino acids of the LANA C terminus are sufficient to inhibit p53-mediated activation of the human BAX promoter, indicating that the CBM is not required for all transcription-related functions. Copyright 2004 American Society for Microbiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331740      PMCID: PMC514975          DOI: 10.1128/JVI.78.18.10074-10085.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma.

Authors:  W Zhong; H Wang; B Herndier; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function.

Authors:  J Torchia; D W Rose; J Inostroza; Y Kamei; S Westin; C K Glass; M G Rosenfeld
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

3.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors.

Authors:  D M Heery; E Kalkhoven; S Hoare; M G Parker
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

4.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

Authors:  T Miyashita; J C Reed
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

5.  Localization and phosphorylation of HP1 proteins during the cell cycle in mammalian cells.

Authors:  E Minc; Y Allory; H J Worman; J C Courvalin; B Buendia
Journal:  Chromosoma       Date:  1999-08       Impact factor: 4.316

Review 6.  Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.

Authors:  Lyubomir A Dourmishev; Assen L Dourmishev; Diana Palmeri; Robert A Schwartz; David M Lukac
Journal:  Microbiol Mol Biol Rev       Date:  2003-06       Impact factor: 11.056

7.  Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity.

Authors:  D G Johnson
Journal:  Oncogene       Date:  1995-11-02       Impact factor: 9.867

8.  Characterization of the human cyclin-dependent kinase 2 gene. Promoter analysis and gene structure.

Authors:  D Shiffman; E E Brooks; A R Brooks; C S Chan; P G Milner
Journal:  J Biol Chem       Date:  1996-05-24       Impact factor: 5.157

9.  The VP16 accessory protein HCF is a family of polypeptides processed from a large precursor protein.

Authors:  A C Wilson; K LaMarco; M G Peterson; W Herr
Journal:  Cell       Date:  1993-07-16       Impact factor: 41.582

10.  Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter.

Authors:  E Neuman; E K Flemington; W R Sellers; W G Kaelin
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

View more
  40 in total

Review 1.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

2.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes.

Authors:  Jianxin You; Viswanathan Srinivasan; Gerald V Denis; William J Harrington; Mary E Ballestas; Kenneth M Kaye; Peter M Howley
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces a strong bend on binding to terminal repeat DNA.

Authors:  Lai-Yee Wong; Angus C Wilson
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.

Authors:  Sofia Corte-Real; Chris Collins; Frederico Aires da Silva; J Pedro Simas; Carlos F Barbas; Yuan Chang; Patrick Moore; Joao Goncalves
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

5.  Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA.

Authors:  Meir Shamay; Anita Krithivas; Jun Zhang; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-18       Impact factor: 11.205

6.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen modulates K1 expression through its cis-acting elements within the terminal repeats.

Authors:  Subhash C Verma; Ke Lan; Tathagata Choudhuri; Erle S Robertson
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Determination of Kaposi's sarcoma-associated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding.

Authors:  Brenna Kelley-Clarke; Mary E Ballestas; Viswanathan Srinivasan; Andrew J Barbera; Takashi Komatsu; Te-Ana Harris; Mia Kazanjian; Kenneth M Kaye
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

8.  Identification of Kaposi's sarcoma-associated herpesvirus LANA regions important for episome segregation, replication, and persistence.

Authors:  Erika De León Vázquez; Vincent J Carey; Kenneth M Kaye
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

9.  Kaposi's Sarcoma-Associated Herpesvirus LANA-Adjacent Regions with Distinct Functions in Episome Segregation or Maintenance.

Authors:  Franceline Juillard; Erika De León Vázquez; Min Tan; Shijun Li; Kenneth M Kaye
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 10.  Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen: Replicating and Shielding Viral DNA during Viral Persistence.

Authors:  Magdalena Weidner-Glunde; Giuseppe Mariggiò; Thomas F Schulz
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.